Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America.

By M. Saag, R. Graybill, R. Larsen, P. Pappas, J. Perfect, W. Powderly, J. Sobel, W. Dismukes. Clinical Infectious Diseases, 2000

1,020 citations recorded by the source corpus.

Subfields: Epidemiology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/e9d4bbc04829e25ae01bb48f940f5fe86c20da48

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. M. Pfaller
2. D. Diekema
3. J. Perfect
4. Nina Singh
5. J. Guinea

In Infectious Diseases

1. M. Pfaller
2. D. Diekema
3. J. Perfect
4. Henry F. Chambers
5. J. Nosanchuk
6. Nina Singh
7. J. Guinea

Citations in the corpus

• Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. (2001, background): “8 mg/kg daily, together with 5-flucytosine (100 mg/kg daily) for at least 2–4 weeks seem reasonable in most instances [33].”
• Immune Reconstitution Inflammatory Syndrome: Emergence of a Unique Syndrome During Highly Active Antiretroviral Therapy (2002, background): “Recent guidelines emphasize the importance of treating intracranial hypertension (59, 130).”
• Practice guidelines for the diagnosis and management of skin and soft-tissue infections. (2005, background): “Fluconazole is often used as initial treatment, for patients with more mild infections, or to complete treatment after the patient has shown clinical and microbiologic improvement with amphotericin B and 5-flucytosine induction therapy [222, 223].”
• Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America (2010, methodology): “Management of Cryptococcal Disease” [1].”
• Epidemiology of Invasive Mycoses in North America (2010, background): “Pharmacologic management of cryptococcal infections usually consists of primary therapy with amphotericin B, with or without flucytosine, followed by maintenance therapy, or in some instances lifelong suppressive therapy, with fluconazole (Saag et al. 2000).”
• The contribution of melanin to microbial pathogenesis (2003, background): “Amphotericin B is a potent broad-spectrum antifungal that is recommended for the treatment of life-threatening cryptococcosis (Saag et al., 2000).”